Karyopharm Therapeutics (KPTI) News Today $0.64 -0.01 (-2.25%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate CommunicationsDecember 9, 2024 | prnewswire.comKaryopharm Therapeutics Provides Endometrial Cancer Program UpdateDecember 3, 2024 | prnewswire.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Sees Large Growth in Short InterestKaryopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) was the recipient of a large growth in short interest in November. As of November 15th, there was short interest totalling 18,930,000 shares, a growth of 7.0% from the October 31st total of 17,690,000 shares. Based on an average trading volume of 747,500 shares, the short-interest ratio is presently 25.3 days.December 3, 2024 | marketbeat.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 2, 2024 | prnewswire.comKaryopharm Therapeutics IncNovember 28, 2024 | money.usnews.comKaryopharm to Participate at the Piper Sandler 36th Annual Healthcare ConferenceNovember 25, 2024 | prnewswire.comKaryopharm Therapeutics (NASDAQ:KPTI) Cut to Hold at StockNews.comStockNews.com downgraded shares of Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday.November 22, 2024 | marketbeat.comKaryopharm appoints Kristin Abate as Chief Accounting OfficerNovember 21, 2024 | markets.businessinsider.comKaryopharm Therapeutics Appoints New Chief Accounting OfficerNovember 21, 2024 | markets.businessinsider.comKaryopharm Therapeutics Announces the Appointment of Chief Accounting OfficerNovember 20, 2024 | prnewswire.comKaryopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and ExpositionNovember 18, 2024 | prnewswire.comGSA Capital Partners LLP Purchases 792,283 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI)GSA Capital Partners LLP increased its holdings in Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) by 80.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,775,700 shares of the company's stockNovember 14, 2024 | marketbeat.comKaryopharm Therapeutics (NASDAQ:KPTI) Stock Rating Upgraded by StockNews.comStockNews.com upgraded shares of Karyopharm Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday.November 14, 2024 | marketbeat.comStrategic Clinical Advances and Revenue Growth Drive Buy Rating for Karyopharm TherapeuticsNovember 9, 2024 | markets.businessinsider.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?November 8, 2024 | finance.yahoo.comLeerink Partnrs Has Optimistic Outlook of KPTI Q4 EarningsKaryopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Equities researchers at Leerink Partnrs boosted their Q4 2024 earnings per share (EPS) estimates for shares of Karyopharm Therapeutics in a report released on Wednesday, November 6th. Leerink Partnrs analyst J. Chang now anticipates thatNovember 8, 2024 | marketbeat.comFY2024 Earnings Forecast for KPTI Issued By HC WainwrightKaryopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Investment analysts at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for Karyopharm Therapeutics in a note issued to investors on Tuesday, November 5th. HC Wainwright analyst E. White now expects that the company wNovember 8, 2024 | marketbeat.comKaryopharm Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 6, 2024 | finance.yahoo.comKaryopharm price target raised to $5 from $4 at Piper SandlerNovember 6, 2024 | markets.businessinsider.comRBC Capital Sticks to Its Buy Rating for Karyopharm Therapeutics (KPTI)November 6, 2024 | markets.businessinsider.comPiper Sandler Raises Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $5.00Piper Sandler increased their price objective on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an "overweight" rating in a research report on Wednesday.November 6, 2024 | marketbeat.comKaryopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ...November 6, 2024 | finance.yahoo.comKaryopharm Therapeutics Inc. Reports Q3 2024 EarningsNovember 6, 2024 | markets.businessinsider.comKaryopharm Therapeutics: Strong Demand and Strategic Initiatives Justify Buy RatingNovember 6, 2024 | markets.businessinsider.comKaryopharm Therapeutics (KPTI) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | msn.comKaryopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | seekingalpha.comAntengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024November 5, 2024 | prnewswire.comKaryopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company ProgressNovember 5, 2024 | prnewswire.comKaryopharm changes endpoint in Phase 3 trial of selinexor in myelofibrosisNovember 1, 2024 | markets.businessinsider.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 1, 2024 | prnewswire.comKaryopharm Therapeutics (KPTI) to Release Earnings on TuesdayKaryopharm Therapeutics (NASDAQ:KPTI) will be releasing earnings before the market opens on Tuesday, November 5, Zacks reports.November 1, 2024 | marketbeat.comKaryopharm Therapeutics' (KPTI) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $7.00 price objective on shares of Karyopharm Therapeutics in a research note on Friday.November 1, 2024 | marketbeat.comPositive Developments and FDA Agreement Boost Karyopharm’s Buy RatingNovember 1, 2024 | markets.businessinsider.comKaryopharm to Report Third Quarter 2024 Financial Results on November 5, 2024October 31, 2024 | prnewswire.comKaryopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in MyelofibrosisOctober 31, 2024 | prnewswire.comKaryopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024October 30, 2024 | prnewswire.comKaryopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Below 200-Day Moving Average - Here's What HappenedKaryopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Below 200-Day Moving Average - Here's WhyOctober 30, 2024 | marketbeat.comHighbridge Capital Management's Strategic Acquisition of Karyopharm Therapeutics SharesOctober 26, 2024 | finance.yahoo.comPiper Sandler Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI)October 23, 2024 | markets.businessinsider.comKaryopharm Therapeutics (NASDAQ:KPTI) Shares Pass Above 50-Day Moving Average - Here's What HappenedKaryopharm Therapeutics (NASDAQ:KPTI) Shares Cross Above Fifty Day Moving Average - Here's WhyOctober 22, 2024 | marketbeat.comAntengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the CountryOctober 17, 2024 | prnewswire.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Holdings Lifted by AQR Capital Management LLCAQR Capital Management LLC grew its position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) by 494.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 748,020 shares of the company's stock after purchasinOctober 14, 2024 | marketbeat.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the five research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and four haOctober 12, 2024 | marketbeat.comCubist Systematic Strategies LLC Buys New Shares in Karyopharm Therapeutics Inc. (NASDAQ:KPTI)Cubist Systematic Strategies LLC purchased a new position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 568,975 shares of the company's stocOctober 5, 2024 | marketbeat.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 1, 2024 | prnewswire.comAntengene Corporation Limited: Antengene Announces XPOVIO (selinexor) Approved for Commercialization in ThailandSeptember 23, 2024 | finanznachrichten.deAntengene Announces XPOVIO® (selinexor) Approved for Commercialization in ThailandSeptember 23, 2024 | prnewswire.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2024 | prnewswire.comKaryopharm to Participate at Upcoming Investor ConferencesSeptember 3, 2024 | prnewswire.comKaryopharm Therapeutics (NASDAQ:KPTI) Stock Crosses Below 200 Day Moving Average of $1.09Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Crosses Below Two Hundred Day Moving Average of $1.09August 31, 2024 | marketbeat.com Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address AI breakthrough about to upend industry (Ad)Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing. I urge you to watch it now. KPTI Media Mentions By Week KPTI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KPTI News Sentiment▼0.000.60▲Average Medical News Sentiment KPTI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KPTI Articles This Week▼02▲KPTI Articles Average Week Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Acelyrin News Today Kamada News Today Trevi Therapeutics News Today Eton Pharmaceuticals News Today Canopy Growth News Today Aquestive Therapeutics News Today Tango Therapeutics News Today Sage Therapeutics News Today Jasper Therapeutics News Today Valneva News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KPTI) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KPTI Stock Alerts